Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection

Michele Caraglia, S. Zappavigna, A. Lombardi, Carla Fierro, Luigi Atripaldi, Tommaso Muto, Daniela Valente, Raffaele Di Francia

Research output: Contribution to journalReview article

Abstract

The introduction of Highly Active Antiretroviral Therapy (HAART) into clinical practice has dramatically changed the natural approach of HIV-related cancers. Several studies have shown that intensive antiblastic chemotherapy (AC) is feasible in HIV-infected patients with cancer, and that the outcome is similar to that of HIV-negative patients receiving the same AC regimens. However, the concomitant use of HAART and AC can result in drug accumulation or possible toxicity with consequent decreased efficacy of one or both classes of drugs. In fact, many AC agents are preferentially metabolized by CYP450 and drug-drug interactions (DDIs) with HAART are common. Therefore, it is important that HIV patients with cancer in HAART receiving AC treatment at the same time receive an individualized cancer management plan based on their liver and renal functions, their level of bone marrow suppression, their mitochondrial dysfunction, and their genotype profile. The rationale of this review is to summarize the existing data on the impact of HAART on the clinical management of cancer patients with HIV/AIDS and DDIs between antiretrovirals and AC. In addition, in order to maximize the efficacy of antiblastic therapy and minimize the risk of drug-drug interaction, a useful list of pharmacogenomic markers is provided.

Original languageEnglish
Article number71
JournalFrontiers in Pharmacology
Volume7
Issue numberMAR
DOIs
Publication statusPublished - Mar 30 2016

Fingerprint

Pharmacogenetics
Highly Active Antiretroviral Therapy
Drug Interactions
HIV Infections
Drug Therapy
HIV
Pharmaceutical Preparations
Neoplasms
Anti-HIV Agents
Bone Marrow
Genotype
Kidney
Liver
Therapeutics

Keywords

  • AIDS
  • Antiblastic chemotherapy
  • Antiretroviral therapy
  • Cancer
  • HIV
  • Pharmacogenomics
  • Polymorphisms cytochrome P450

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection. / Caraglia, Michele; Zappavigna, S.; Lombardi, A.; Fierro, Carla; Atripaldi, Luigi; Muto, Tommaso; Valente, Daniela; Di Francia, Raffaele.

In: Frontiers in Pharmacology, Vol. 7, No. MAR, 71, 30.03.2016.

Research output: Contribution to journalReview article

Caraglia, Michele ; Zappavigna, S. ; Lombardi, A. ; Fierro, Carla ; Atripaldi, Luigi ; Muto, Tommaso ; Valente, Daniela ; Di Francia, Raffaele. / Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection. In: Frontiers in Pharmacology. 2016 ; Vol. 7, No. MAR.
@article{d9b8e36a25bf4f878272d4a21e56b025,
title = "Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection",
abstract = "The introduction of Highly Active Antiretroviral Therapy (HAART) into clinical practice has dramatically changed the natural approach of HIV-related cancers. Several studies have shown that intensive antiblastic chemotherapy (AC) is feasible in HIV-infected patients with cancer, and that the outcome is similar to that of HIV-negative patients receiving the same AC regimens. However, the concomitant use of HAART and AC can result in drug accumulation or possible toxicity with consequent decreased efficacy of one or both classes of drugs. In fact, many AC agents are preferentially metabolized by CYP450 and drug-drug interactions (DDIs) with HAART are common. Therefore, it is important that HIV patients with cancer in HAART receiving AC treatment at the same time receive an individualized cancer management plan based on their liver and renal functions, their level of bone marrow suppression, their mitochondrial dysfunction, and their genotype profile. The rationale of this review is to summarize the existing data on the impact of HAART on the clinical management of cancer patients with HIV/AIDS and DDIs between antiretrovirals and AC. In addition, in order to maximize the efficacy of antiblastic therapy and minimize the risk of drug-drug interaction, a useful list of pharmacogenomic markers is provided.",
keywords = "AIDS, Antiblastic chemotherapy, Antiretroviral therapy, Cancer, HIV, Pharmacogenomics, Polymorphisms cytochrome P450",
author = "Michele Caraglia and S. Zappavigna and A. Lombardi and Carla Fierro and Luigi Atripaldi and Tommaso Muto and Daniela Valente and {Di Francia}, Raffaele",
year = "2016",
month = "3",
day = "30",
doi = "10.3389/fphar.2016.00071",
language = "English",
volume = "7",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "MAR",

}

TY - JOUR

T1 - Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection

AU - Caraglia, Michele

AU - Zappavigna, S.

AU - Lombardi, A.

AU - Fierro, Carla

AU - Atripaldi, Luigi

AU - Muto, Tommaso

AU - Valente, Daniela

AU - Di Francia, Raffaele

PY - 2016/3/30

Y1 - 2016/3/30

N2 - The introduction of Highly Active Antiretroviral Therapy (HAART) into clinical practice has dramatically changed the natural approach of HIV-related cancers. Several studies have shown that intensive antiblastic chemotherapy (AC) is feasible in HIV-infected patients with cancer, and that the outcome is similar to that of HIV-negative patients receiving the same AC regimens. However, the concomitant use of HAART and AC can result in drug accumulation or possible toxicity with consequent decreased efficacy of one or both classes of drugs. In fact, many AC agents are preferentially metabolized by CYP450 and drug-drug interactions (DDIs) with HAART are common. Therefore, it is important that HIV patients with cancer in HAART receiving AC treatment at the same time receive an individualized cancer management plan based on their liver and renal functions, their level of bone marrow suppression, their mitochondrial dysfunction, and their genotype profile. The rationale of this review is to summarize the existing data on the impact of HAART on the clinical management of cancer patients with HIV/AIDS and DDIs between antiretrovirals and AC. In addition, in order to maximize the efficacy of antiblastic therapy and minimize the risk of drug-drug interaction, a useful list of pharmacogenomic markers is provided.

AB - The introduction of Highly Active Antiretroviral Therapy (HAART) into clinical practice has dramatically changed the natural approach of HIV-related cancers. Several studies have shown that intensive antiblastic chemotherapy (AC) is feasible in HIV-infected patients with cancer, and that the outcome is similar to that of HIV-negative patients receiving the same AC regimens. However, the concomitant use of HAART and AC can result in drug accumulation or possible toxicity with consequent decreased efficacy of one or both classes of drugs. In fact, many AC agents are preferentially metabolized by CYP450 and drug-drug interactions (DDIs) with HAART are common. Therefore, it is important that HIV patients with cancer in HAART receiving AC treatment at the same time receive an individualized cancer management plan based on their liver and renal functions, their level of bone marrow suppression, their mitochondrial dysfunction, and their genotype profile. The rationale of this review is to summarize the existing data on the impact of HAART on the clinical management of cancer patients with HIV/AIDS and DDIs between antiretrovirals and AC. In addition, in order to maximize the efficacy of antiblastic therapy and minimize the risk of drug-drug interaction, a useful list of pharmacogenomic markers is provided.

KW - AIDS

KW - Antiblastic chemotherapy

KW - Antiretroviral therapy

KW - Cancer

KW - HIV

KW - Pharmacogenomics

KW - Polymorphisms cytochrome P450

UR - http://www.scopus.com/inward/record.url?scp=84973122122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973122122&partnerID=8YFLogxK

U2 - 10.3389/fphar.2016.00071

DO - 10.3389/fphar.2016.00071

M3 - Review article

VL - 7

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 71

ER -